Skip to main content
. 2019 Oct 31;20(21):5447. doi: 10.3390/ijms20215447

Figure 4.

Figure 4

New potential therapeutic targets for conjunctival melanoma. (A) Telomerase reverse transcriptase (TERT) is a catalytic subunit of the telomerase enzyme that catalyzes the addition of repetitive sequences in the terminal TTAGGG of chromosomes. TERT promoter mutations, which cause an increased TERT expression, are detectable in 32–41% of conjunctival melanomas. (B) Enhancer of zeste homolog 2 (EZH2) is a histone methyltransferase which catalyses trimethylation of lysine 27 in histone H3 (H3K27me3), leading to transcriptional silencing of oncosuppressors. EZH2 is highly expressed in 50% of primary conjunctival melanomas and 88% of lymph node metastases.